Compare ABR & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABR | CRVS |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2003 | 2016 |
| Metric | ABR | CRVS |
|---|---|---|
| Price | $4.98 | $14.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $9.90 | ★ $30.17 |
| AVG Volume (30 Days) | ★ 3.9M | 785.6K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 15.42% | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.73 | $5.03 |
| 52 Week High | $12.58 | $26.95 |
| Indicator | ABR | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 44.16 | 61.02 |
| Support Level | $4.99 | $14.24 |
| Resistance Level | $5.43 | $16.66 |
| Average True Range (ATR) | 0.19 | 0.68 |
| MACD | 0.01 | 0.16 |
| Stochastic Oscillator | 40.67 | 86.63 |
Arbor Realty Trust Inc is a specialized real estate finance company. It invests in a diversified portfolio of structured finance assets in the multifamily, SFR, and commercial real estate markets, consisting of bridge and mezzanine loans, including junior participating interests in first mortgages, preferred, and direct equity. In addition, it may also directly acquire real property and invest in real estate-related notes and certain mortgage-related securities. The company has two business segments, Structured Business and Agency Business. It generates a majority of its revenue from the Structured Business Segment.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.